What’s Next With New Ketamine Depression Drug? At IOL, a Study With Kids.

Ketamine
Print icon

While the nation is clamoring for more information about the new treatment approved by the Food and Drug Administration for depression, Drs. Andrew Winokur and Mirela Loftus are quietly working on the next application.

A nasal spray containing the active ingredient Esketamine — a chemical “relative” of the drug ketamine that has served as an anesthetic for decades – was approved for use against severe (treatment resistant) cases of depression in adults. Dr. Loftus, a child and adolescent psychiatrist, has been part of a research team affiliated with the Institute of Living testing various applications of the drug, marketed as Spravato, for depression.

The initial results in patients, she said, are astonishing,

“There are people who have been in our study for two or three years and every one of them has had the same story about how life-changing this is for them,” Dr. Loftus said.

Esketamine alters the chemical functioning of the brain in a manner that is different from antidepressant drugs currently on the market. Besides affecting the chemical shift in the brain that sparks depression, Esketamine works on the glutamate, affecting the synaptic plasticity. In other words, it potentially changes the connections or synapses in the brain that contribute to depression.

“The mechanism of action here is very different than any other anti-depression medication on the market now,” Dr. Loftus said.

A controlled substance, Esketamine must be administered in an approved clinic environment in which the patient is monitored for an hour or two for any adverse reaction. Such reactions, she said, can include elevated blood pressure and an altered perception of reality such as dissociation, dizziness, sleepiness or seeing double.

A variety of questions about the medication remain, however, and Dr. Loftus said researchers will continue to seek answers. For example, while there have been appropriate concerns about abuse potential related to the inappropriate use of ketamine (sometimes referred to as Special K), in carefully controlled clinical trials of Esketamine, problems with dependence or abuse have not been identified to date, although more research on this topic is needed.

“There has not been a long enough period of observation to know the answer to that,” she began. “But, why would I give a drug of abuse? It’s a completely different way of delivery and dosing than in the street.”

She is also involved in other research projects through the IOL’s Clinical Trials Unit, including one investigating the use of Esketamine in children and adolescents.

“The IOL is one of the few sites in the world using this in children and adolescents. We just recruited the second adolescent in the world for our study,” Dr. Loftus said, noting that the work is focused on children and adolescents presenting with suicidal thoughts, the most severe form of depression.

In addition, the IOL team is hoping to discover how to shorten the patient reaction time to the medication. Currently, Esketamine takes a few days to show an effect, as opposed to weeks for existing antidepressants. Further research is needed to see if there are certain conditions in which the effect would be even shorter, even just hours.

For more information about treatment for depression at the Hartford HealthCare Behavioral Health Network, click here. For learn more about the Institute of Living’s Clinical Trials Unit, click here.

 

 


What's New

Kelly Posner

Suicide Questionnaire Could Be the Next ‘Miracle Drug’

Major breakthroughs have been made for many health issues – genetic testing for cancer, antibiotics for infections, new procedures for heart disease. But what about suicide, which is the 10th-leading cause of death in the United States? The answer is simple — ask the right questions, according to Kelly Posner,...

Therapy Session

When Medical Illness Causes Mental Health Problems in Youths

As if struggling with chronic medical illness is not challenging enough for young adults, research shows they are also far more likely to develop mental illness than those not facing physical challenges or limitations. A two-year research study released by the Cambridge Health Alliance followed 48,000 youth between ages 6...

Golden Gate Bridge

How Suicide Prevention Became Part of This Officer’s Job

When Kevin Briggs was sent out on his California Highway Patrol motorcycle to monitor the Golden Gate Bridge in San Francisco, he had no training in interacting with suicidal people but the pain and anguish he saw in their eyes affected him instantly and deeply. “I just wanted to be...

Recovery sign

New Program to Train Recovery Support Specialists

Sharing personal stories and helping others can be a rewarding part of the recovery process for many people, and the Hartford HealthCare Behavioral Health Network has created a way to make that happen. The Recovery Leadership Academy — an 80-hour certificate program for people in recovery from mental health and/or...


10 Signs of Mental Health Issues in Men

We know – and joke about – how, generally, men don’t particularly like seeing doctors for physical ailments, but getting them to see a professional for behavioral health issues is nearly impossible. Dr. Alexander Miano, physician psychiatrist at the outpatient behavioral health clinic at Backus Hospital in Norwich, has been at...


Natchaug Adds Groton To College Student Treatment Program

Going off to college seems picture-perfect in advertising and university catalogs, but the reality can be much more stressful and even debilitating for some young adults. Many relocate from their parents’ home to a dorm room where loneliness can set in. All must function more independently than ever, with fewer...